Cubit Diagnostics Secures New Financing to Advance Integrated Point-of-Care Testing Platform

Point-of-care diagnostics has spent years talking like a nightclub flyer. “Fast.” “Accessible.” “Next generation.” Everybody promising the future while patients still sit in exam rooms playing the ancient medical tradition known as “waiting around wondering what’s growing in their bloodstream.” Meanwhile, the real constraint was never just speed. It was fragmentation. 1 machine for molecular. Another for immunoassays. Another invoice. Another workflow.

That is why Cubit Diagnostics closing its latest SAFE financing round matters more than the headline lets on. Quiet rounds in diagnostics tend to carry the loudest implications because the people wiring capital into this category know 1 thing: if you can collapse complexity in healthcare, you are not just building a product. You are removing friction from 1 of the most expensive games on Earth.

Kunal Sur, Co-founder & CEO of Cubit Diagnostics, is steering directly into that problem with a benchtop platform built to integrate molecular testing and immunoassays into a single workflow. Not 5 devices stitched together with optimism and PowerPoint transitions. 1 platform. 1 system. Less chaos between patient intake and clinical action. Cubit Diagnostics is targeting results in 15 minutes or less with under 2 minutes of hands-on time, while supporting up to 8 targets per run. That is not marketing glitter. That is operational math.

The company is advancing its CT/NG/TV molecular assay toward design freeze while simultaneously expanding its immunoassay menu. Most startups spend years trying to survive 1 lane. Cubit Diagnostics is building infrastructure for multiple testing modalities at the same time. Different sport entirely.

Another detail deserves attention. The platform is designed for doctor’s offices and pharmacies, not science projects hidden behind layers of hospital bureaucracy and endless compliance binders. Diagnostics only changes healthcare when it leaves the fortress and reaches the point of care where decisions actually happen.

Adding Robert Bujarski and Mark Paiz to the Board of Directors also says a lot without yelling. You do not bring in operators with deep diagnostics and commercialization experience unless the road ahead starts looking less theoretical and more executable. Smart money watches technology. Experienced operators watch timing.

Cubit Diagnostics feels like 1 of those companies building in the spaces most people overlook because the work is harder, the regulations are brutal, and the science cannot hide behind hype language. The company also previously secured a $2.6M NIH RADx Tech award to support development of its integrated platform, another signal that serious institutions are paying attention to where point-of-care diagnostics is heading next.